The Grünenthal charter
on the responsible use of opioids
As a leading manufacturer of pain treatments including opioids, Grünenthal is aware that, besides the benefits these medicines can provide, they also carry risks – for instance inappropriate use, misuse, abuse, addiction (opioid use disorder, OUD) and diversion. We share the broad consensus with the pain community that the opioid crisis in some countries needs to be addressed with high urgency.Grünenthal’s charter on the responsible use of opioids (summarized below) sets out our continuing commitment to explore and endorse measures that minimize the risk of inappropriate and illegitimate use of prescription opioids – while striving to ensure that individual patients with a clear need for opioid-based pain relief are not denied access.
An urgent and measured response to the opioid crisis is required